New Onset of Giant Cell Arteritis following ChAdOx1-S (Vaxevria®) Vaccine Administration

Vaccines (Basel). 2023 Feb 13;11(2):434. doi: 10.3390/vaccines11020434.

Abstract

We report a 78-year-old man presenting with persistent headaches in vertex and temporo-parietal area; fatigue, worsening after walking; jaw claudication; scotomas; pharyngodynia; and dry cough after the second dose of the SARS-CoV-2 vaccine (ChAdOx1-S) administration. Laboratory findings showed an elevated C-reactive protein level and FDG-CT PET showed evidence of active large vessel vasculitis with diffuse abnormal artery uptake. Under suspicion of vasculitis, a temporal arteries biopsy was performed; the histopathologic findings demonstrated the transmural inflammatory infiltrate with giant cells, compatible with giant cell arteritis. Although the overall incidence of vaccine-triggered autoimmunity is low, rheumatologists worldwide should be aware of autoimmune diseases as a new potential adverse event of vaccines.

Keywords: COVID-19; adverse events; giant cell arteritis; vaccines.

Publication types

  • Case Reports

Grants and funding

This research received no external funding.